Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice

Brain Research

Volumn 1371, Issue , 2011, Pages 161-170

  Kurata, Tomoko ^a   Miyazaki, Kazunori ^a   Kozuki, Miki ^a   Panin, Violeta Lukic ^a   Morimoto, Nobutoshi ^a   Ohta, Yasuyuki ^a   Nagai, Makiko ^a   Ikeda, Yoshio ^a   Matsuura, Tohru ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Atorvastatin; Pitavastatin; Transgenic mouse

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TAU PROTEIN; TRIACYLGLYCEROL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN WEIGHT; COGNITION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BODY WEIGHT; BRAIN; COGNITION DISORDERS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MAZE LEARNING; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; ORGAN SIZE; PHOSPHORYLATION; PLAQUE, AMYLOID; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLES; QUINOLINES; TAU PROTEINS;

MUS; MUS MUSCULUS;

EID: 78651365099     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.11.067     Document Type: Article

References (32)

1. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 1992 631 639
2. M. Boimel, N. Grigoriadis, A. Lourbopoulos, O. Touloumi, D. Rosenmann, O. Abramsky, and H. Rosenmann Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy J. Neuropathol. Exp. Neurol. 68 2009 314 325
3. C.M. Carlsson, C.E. Gleason, T.M. Hess, K.A. Moreland, H.M. Blazel, R.L. Koscik, N.T. Schreiber, S.C. Johnson, C.S. Atwood, L. Puglielli, B.P. Hermann, P.E. McBride, J.H. Stein, M.A. Sager, and S. Asthana Effect s of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease J. Alzheimers Dis. 13 2008 187 197
4. N.B. Chauhan, G.J. Siegel, and D.L. Feinstein Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain Neurochem. Res. 29 2004 1897 1911
5. M. Cimino, P. Gelosa, A. Gianella, E. Nobili, E. Tremoli, and L. Sironi Statins: multiple mechanisms of action in the ischemic brain Neuroscientist 13 2007 208 213
6. A. Cordle, and G. Landreth 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses J. Neurosci. 25 2005 299 307
7. F.G. De Felice, D. Wu, M.P. Lambert, S.J. Fernandez, P.T. Velasco, P.N. Lacor, E.H. Bigio, J. Jerecic, P.J. Acton, P.J. Shughrue, E. Chen-Dodson, G.G. Kinney, and W.L. Klein Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers Neurobiol. Aging 29 2008 1334 1347
8. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther, and T. Hartmann Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc. Natl Acad. Sci. USA 98 2001 5856 5861
9. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 1996 99 102
10. M. Hu, J.F. Waring, M. Gopalakrishnan, and J. Li Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells J. Neurochem. 106 2008 1371 1377
11. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
12. K. Kajinami, H. Mabuchi, and Y. Saito NK-104: a novel synthetic HMG-CoA reductase inhibitor Expert Opin. Investig. Drugs 9 2000 2653 2661
13. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe, and S.G. Younkin Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease J. Neurosci. 21 2001 372 381
14. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
15. W.L. Klein, G.A. Krafft, and C.E. Finch Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24 2001 219 224
16. 1-42 are potent central nervous system neurotoxins Proc. Natl Acad. Sci. USA 95 1998 6448 6453
17. L. Li, D. Cao, H. Kim, R. Lester, and K. Fukuchi Simvastatin enhances learning and memory independent of amyloid load in mice Ann. Neurol. 60 2006 729 739
18. G. Li, E.B. Larson, J.A. Sonnen, J.B. Shofer, E.C. Petrie, A. Schantz, E.R. Peskind, M.A. Raskind, J.C. Breitner, and T.J. Montine Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease Neurology 28 2007 878 885
19. S. Morikawa, M. Umetani, S. Nakagawa, H. Yamazaki, H. Suganami, K. Inoue, M. Kitahara, T. Hamakubo, T. Kodama, and Y. Saito Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells J. Atheroscler. Thromb. 7 2000 138 144
20. P. Nachtigal, G. Jamborova, N. Pospisilova, K. Pospechova, D. Solichova, P. Zdansky, and V. Semecky Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis J. Pharm. Pharm. Sci. 9 2006 222 230
21. S. Nomura, N. Inami, A. Shouzu, S. Omoto, Y. Kimura, N. Takahashi, A. Tanaka, F. Urase, Y. Maeda, H. Ohtani, and T. Iwasaka The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients Platelets 20 2009 16 22
22. M. Okada, A. Tamura, A. Urae, T. Nakagomi, T. Kirino, K. Mine, and M. Fujiwara Long-term spatial cognitive impairment following middle cerebral artery occlusion in rats. A behavioral study J. Cereb. Blood Flow. Metab. 15 1995 505 512
23. S.S. Petanceska, S. DeRosa, V. Olm, N. Diaz, A. Sharma, T. Thomas-Bryant, K. Duff, M. Pappolla, and L.M. Refolo Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19 2002 155 161
24. L.M. Refolo, M.A. Pappolla, B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G.S. Tint, K. Sambamurti, and K. Duff Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model Neurobiol. Dis. 7 2000 321 331
25. L.M. Refolo, M.A. Pappolla, J. LaFrancois, B. Malester, S.D. Schmidt, T. Thomas-Bryant, G.S. Tint, R. Wang, M. Mercken, S.S. Petanceska, and K.E. Duff A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease Neurobiol. Dis. 8 2001 890 899
26. E.D. Roberson, K. Scearce-Levie, J.J. Palop, F. Yan, I.H. Cheng, T. Wu, H. Gerstein, G.Q. Yu, and L. Mucke Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model Science 316 2007 750 754
27. D.J. Selkoe Alzheimer's disease is a synaptic failure Science 298 2002 789 791
28. D.L. Sparks, D.J. Connor, M.N. Sabbagh, R.B. Peterson, J. Lopez, and P. Browne Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: result of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial Acta Neurol. Scand. 114 suppl 185 2006 3 7
29. H. Suzuki, T. Aoki, T. Tamaki, F. Sato, M. Kitahara, and Y. Saito Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs Atherosclerosis 146 1999 259 270
30. T. Tomiyama, S. Matsuyama, H. Iso, T. Umeda, H. Takuma, K. Ohnishi, K. Ishibashi, R. Teraoka, N. Sakama, T. Yamashita, K. Nishitsuji, K. Ito, H. Shimada, M.P. Lambert, W.L. Klein, and H. Mori A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo J. Neurosci. 30 2010 4845 4856
31. X.K. Tong, N. Nicolakakis, P. Fernandes, B. Ongali, J. Brouillette, R. Quirion, and E. Hamel Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice Neurobiol. Dis. 35 2009 406 414
32. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 2000 1439 1443